magrolimab + bortezomib + dexamethasone

**Magrolimab + bortezomib + dexamethasone** is an investigational combination regimen under evaluation for the treatment of relapsed/refractory multiple myeloma. - **Magrolimab** is a first-in-class humanized monoclonal antibody that targets CD47, a cell surface protein that functions as a ‘do not eat me’ signal to evade phagocytosis by macrophages. By blocking CD47, magrolimab promotes macrophage-mediated phagocytosis of myeloma cells. - **Bortezomib** is a reversible proteasome inhibitor that disrupts the 26S proteasome’s role in degrading ubiquitinated proteins, leading to cell cycle arrest and apoptosis in myeloma cells. - **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and antineoplastic effects, commonly used to enhance the efficacy of chemotherapeutic agents in myeloma regimens. Clinical trials (notably NCT04892446) are ongoing to evaluate the safety and efficacy of this regimen in patients with relapsed/refractory multiple myeloma[1][2][4][5][7].